Can stem cells help neurological diseases?

UC-MSCs and exosomes may help modulate inflammation, support neuron protection, and improve function in selected neurological conditions.

What conditions are treated at OmniStem?

Parkinson’s disease, MS, ALS, neuropathies, and cognitive decline are commonly evaluated and supported with personalized protocols.

How are treatments administered?

Primarily via intravenous infusions of UC-MSCs and exosomes; in some cases, targeted applications are considered based on medical evaluation.

How soon might results appear?

Timelines vary by diagnosis and severity; many patients report progressive changes over weeks to months as inflammation subsides.

Is neurological stem cell therapy safe?

Biologics are GMP-processed and administered by trained clinicians; side effects are typically mild and temporary, such as fatigue.

Stem Cell Therapy for Neurological Disorders

Advancing Neurological Care with UC-MSC and Exosome Therapies

Learn how umbilical cord-derived stem cell and exosome therapy for neurological disorders are being studied as a complementary approach for patients living with stroke, Parkinson’s disease, traumatic brain injury, and other conditions of the central nervous system.

Regenerative Medicine for Neurological Health

For decades, care for most neurological conditions has centered on managing symptoms and slowing progression. That leaves many patients doing the right things, medication, neurorehabilitation, physical therapy, and still living with limits on movement, cognition, or independence.

Regenerative medicine for neurological disorders takes a different angle. Rather than targeting symptoms alone, UC-MSC and exosome protocols are studied for their effect on the biological environment around injured nerve tissue: inflammation, blood supply, and cell-to-cell signaling.

How UC-MSC and Exosomes Therapies Support Neurological Function?

UC-MSCs and their derived exosomes are studied as a combined approach, working through several mechanisms that overlap rather than acting in isolation.

UC-MSC

UC-MSCs are multipotent cells derived from umbilical cord tissue. In controlled laboratory settings they have shown the capacity to differentiate into several cell types, including neural lineages. In the injured nervous system, however, they are primarily thought to work through paracrine signaling, releasing factors that may support the surrounding tissue, rather than replacing damaged neurons themselves. Whether they can do the latter clinically remains under investigation.

UC-MSC Derived Exosomes

Exosomes are tiny vesicles released by UC-MSCs. Think of them as messengers: they carry proteins, growth factors, and genetic material that help cells communicate. Because of their size, they are studied for their ability to reach tissue that whole-cell delivery may not, including across the blood brain barrier.

Inflammation Regulation

Many neurological conditions involve chronic inflammation in the central nervous system, which can worsen existing damage. UC-MSCs release anti-inflammatory factors that may help modulate that inflammatory environment.

Neuroprotection and Neurotrophic Support

UC-MSCs secrete neurotrophic factors, signaling proteins associated with neuron survival and resilience. These are studied for their potential to help protect neurons from ongoing injury, an area of particular research interest in traumatic brain injury and stroke recovery.

Angiogenesis and Blood Flow

UC-MSCs are studied for their role in supporting the formation of new blood vessels. Where blood supply to nerve tissue has been compromised, improved perfusion is considered relevant to recovery.

Cell Communication and Neuroplasticity

Exosomes carry proteins, lipids, and RNA between cells. In the nervous system, this signaling is being studied for its influence on communication between neurons and glial cells, the basis of neuroplasticity, the brain's capacity to reorganize function after injury.

Neuronal Growth

UC-MSCs release neurotrophic factors that directly support the growth, survival, and resilience of neurons, strengthening neurological recovery.

Neurological Conditions Being Studied with UC-MSC and Exosome Therapies

UC-MSC and exosome protocols are being studied across a range of neurological and neurodegenerative conditions. The list below reflects areas of current clinical investigation and the conditions OmniStem’s medical team evaluates.

• Multiple Sclerosis (MS)
• Parkinson’s Disease
• Traumatic Brain Injury

• Guillain-Barré Syndrome
• Stroke Recovery
• Spinal Cord Injury

How Regenerative Protocols Fit Alongside Standard Neurological Care

Most patients and families arrive here already under neurological care. Understanding where a regenerative protocol sits relative to that care is the point of the table below — this is a complementary option to discuss, not a replacement for treatment your neurologist has prescribed.

Approach	What it does	What to keep in mind
Symptom-directed medication	Manages symptoms such as spasticity, tremor, pain, and fatigue	Necessary for many patients. Does not address the underlying tissue environment
Disease-modifying therapies	Slow progression in specific diagnoses, such as MS	Available for some conditions only. Response varies
Physical and occupational therapy	Rebuilds and preserves function, supports neuroplasticity	Central to recovery. Progress can plateau
Surgical or interventional procedures	Structural correction or device-based symptom control	Invasive. Indicated for a narrow set of cases
Supportive therapies (HBOT, PRGF)	Support oxygenation and the local healing environment	Used at OmniStem alongside cellular protocols, not in place of them
UC-MSC + exosome protocols	Studied for effects on inflammation, blood supply, and cell signaling around injured nerve tissue	Investigational. Physician evaluation required to confirm candidacy

Patients continue medication and rehabilitation before, during, and after a regenerative protocol unless their treating physician directs otherwise. Rehabilitation in particular is not optional: much of the research interest in this field concerns supporting the environment in which rehabilitation happens, which means the rehab work still has to be done.

Am I a candidate? Neurology is the area where candidacy is assessed most conservatively of anything OmniStem offers. Diagnosis, disease stage, time since injury, imaging, current medications, and overall health all factor in, as does whether the goals a patient or family is hoping for are realistic for the evidence that exists. Some patients who inquire are told a protocol is not appropriate for their situation. That determination is made through full physician evaluation during the CARE process, not by self-assessment.

Protocol Principles: Evaluation, Rehabilitation, and Long-Term Follow-Up

Evidence-Based Evaluation Protocols are guided by the current peer-reviewed literature and findings from ongoing clinical trials, alongside clinical experience. Where evidence for a condition is early-stage, we say so.

Individualized Protocol Design Every plan is built around diagnosis, disease stage, imaging, and current treatment, including the medications and rehabilitation already in place.

Rehabilitation-Integrated Cellular protocols are coordinated with physiotherapy and supportive therapies, because functional gains in neurology are built through rehabilitation.

Long-Term Follow-Up Neurological change is gradual. Response is reassessed over months rather than weeks, and long term follow-up is part of protocol design.

Frequently Asked Questions

How do UC-MSC exosomes reach the brain?

Exosomes are microscopic vesicles studied for their ability to cross biological barriers, including the blood–brain barrier. Depending on the delivery route used, they may reach areas of the brain and nervous system, where the proteins and genetic material they carry are studied for effects on inflammation, neuron protection, and repair signaling.

What neurological conditions can be treated with this therapy?

Regenerative approaches using UC-MSCs and exosomes are investigational and have shown potential in conditions such as stroke recovery, multiple sclerosis, Parkinson's disease, Alzheimer's disease, spinal cord injury, and amyotrophic lateral sclerosis (ALS). Each case requires careful evaluation, as suitability varies widely depending on diagnosis and disease stage.

How are these treatments thought to work?

The therapies work through several mechanisms:

• Reducing inflammation that worsens nerve damage.
• Protecting existing neurons from further injury through the release of growth factors.
• Promoting angiogenesis, or new blood vessel growth, to improve oxygen and nutrient supply.
• Supporting neuroplasticity by influencing communication between neurons and glial cells.

Together, these processes aim to create a more favorable environment for recovery, although outcomes differ from patient to patient.

Can stem cell therapy help with stroke recovery?

UC-MSC and exosome protocols are being studied for mechanisms relevant to stroke recovery, including inflammation, blood supply to affected tissue, and the signaling associated with neuroplasticity. Research interest is in supporting the rehabilitation process rather than reversing the original injury, and the evidence is still developing. Time since the stroke, imaging findings, current rehabilitation progress, and overall health all factor into whether a physician considers a protocol appropriate.

Will I stop my current neurological medication or rehabilitation?

No. UC-MSC and exosome protocols are evaluated as a complementary approach alongside neurologist-directed care, not as a replacement for it. Patients continue prescribed medication, including disease-modifying therapies, and their physical or occupational therapy program unless their treating physician directs otherwise. Rehabilitation is considered an integral part of the protocol, not something the therapy replaces.

How long does it take to see results?

Some patients report changes in energy, cognition, or mobility within weeks, while others notice improvements gradually over several months. Because neurological healing is complex, progress often occurs slowly and requires continued evaluation over 6–12 months.